Corporate ActionMay 20, 2026, 04:37 PM
ProMIS Neurosciences Increases Stock Option Plan Shares by 900,000
AI Summary
ProMIS Neurosciences Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the number of Common Shares available for issuance by 900,000. Additionally, seven director nominees were elected, and Baker Tilly US, LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved an amendment to the 2025 Stock Option and Incentive Plan.
- The 2025 Plan Amendment increases shares available for issuance by 900,000 Common Shares.
- Seven director nominees were elected to serve until the 2027 annual meeting.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for 2026.
- Total Common Shares outstanding as of record date: 8,967,693.
- Approximately 53.1% of Common Shares (4,762,024) were present or represented at the meeting.
- The 2025 Plan Amendment received 3,352,388 votes For and 774,193 votes Against.
Price Impact
More from PMN